Trivium Point Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.18M | Buy |
20,481
+12,590
| +160% | +$723K | 0.11% | 174 |
|
|
2026
Q1 | $479K | Sell |
7,891
-2,885
| -27% | -$168K | 0.09% | 195 |
|
|
2025
Q4 | $581K | Buy |
10,776
+2,212
| +26% | +$106K | 0.06% | 228 |
|
|
2025
Q3 | $386K | Sell |
8,564
-2,509
| -23% | -$117K | 0.04% | 266 |
|
|
2025
Q2 | $513K | Sell |
11,073
-208
| -2% | -$10.2K | 0.06% | 235 |
|
|
2025
Q1 | $688K | Buy |
11,281
+1,489
| +15% | +$86.8K | 0.09% | 200 |
|
|
2024
Q4 | $554K | Buy |
9,792
+1,899
| +24% | +$106K | 0.07% | 214 |
|
|
2024
Q3 | $461K | Buy |
7,893
+620
| +9% | +$29.1K | 0.06% | 228 |
|
|
2024
Q2 | $302K | Buy |
7,273
+1,124
| +18% | +$50.3K | 0.05% | 248 |
|
|
2024
Q1 | $333K | Buy |
6,149
+1,493
| +32% | +$76.1K | 0.07% | 185 |
|
|
2023
Q4 | $239K | Sell |
4,656
-257
| -5% | -$13.5K | 0.06% | 182 |
|
|
2023
Q3 | $281K | Sell |
4,913
-38
| -0.8% | -$2.33K | 0.08% | 165 |
|
|
2023
Q2 | $317K | Sell |
4,951
-279
| -5% | -$18.7K | 0.09% | 165 |
|
|
2023
Q1 | $362K | Sell |
5,230
-38
| -0.7% | -$2.68K | 0.1% | 160 |
|
|
2022
Q4 | $385K | Sell |
5,268
-38
| -0.7% | -$2.87K | 0.11% | 153 |
|
|
2022
Q3 | $373K | Sell |
5,306
-276
| -5% | -$20K | 0.12% | 154 |
|
|
2022
Q2 | $419K | Sell |
5,582
-1,837
| -25% | -$140K | 0.13% | 154 |
|
|
2022
Q1 | $559K | Sell |
7,419
-499
| -6% | -$33.5K | 0.12% | 162 |
|
|
2021
Q4 | $494K | Buy |
7,918
+917
| +13% | +$53.8K | 0.1% | 165 |
|
|
2021
Q3 | $413K | Sell |
7,001
-16,832
| -71% | -$1.11M | 0.1% | 165 |
|
|
2021
Q2 | $1.59M | Sell |
23,833
-2,513
| -10% | -$164K | 0.4% | 88 |
|
|
2021
Q1 | $1.66M | Sell |
26,346
-2,735
| -9% | -$170K | 0.45% | 82 |
|
|
2020
Q4 | $1.81M | Sell |
29,081
-1,527
| -5% | -$93.9K | 0.52% | 60 |
|
|
2020
Q3 | $1.84M | Sell |
30,608
-1,047
| -3% | -$63K | 0.65% | 49 |
|
|
2020
Q2 | $1.91M | Buy |
31,655
+24,179
| +323% | +$1.45M | 0.75% | 40 |
|
|
2020
Q1 | $435K | Buy |
7,476
+3,740
| +100% | +$229K | 0.22% | 105 |
|
|
2019
Q4 | $240K | Sell |
3,736
-1,049
| -22% | -$60.1K | 0.09% | 148 |
|
|
2019
Q3 | $243K | Buy |
4,785
+339
| +8% | +$15.9K | 0.11% | 140 |
|
|
2019
Q2 | $202K | Sell |
4,446
-376
| -8% | -$17.5K | 0.09% | 159 |
|
|
2019
Q1 | $230K | Buy |
4,822
+810
| +20% | +$40.3K | 0.11% | 146 |
|
|
2018
Q4 | $209K | Buy |
+4,012
| New | +$216K | 0.13% | 131 |
|
Other funds holding BMY
Trivium Point Advisory's BMY Position: Q2 2026 in Review
Trivium Point Advisory increased its Bristol-Myers Squibb (BMY) stake by 160% in Q2 2026, buying an estimated $723K and bringing the position to 20,481 shares worth $1.18M. The position accounts for 0.11% of the portfolio, ranked #174.
Trivium Point Advisory first reported a position in BMY in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.91M in Q2 2020. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Trivium Point Advisory held 20,481 shares of Bristol-Myers Squibb worth $1.18M as of Q2 2026.
- Trivium Point Advisory bought 12,590 Bristol-Myers Squibb shares in Q2 2026, an estimated $723K.
- Bristol-Myers Squibb made up 0.11% of Trivium Point Advisory's portfolio in Q2 2026, its #174 holding.
- Trivium Point Advisory first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 31 quarters since.
- Trivium Point Advisory's Bristol-Myers Squibb position peaked at $1.91M in Q2 2020.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.